Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

75.82
-6.0800-7.42%
Post-market: 75.820.00000.00%19:15 EDT
Volume:1.43M
Turnover:110.19M
Market Cap:5.18B
PE:-24.41
High:83.65
Open:81.00
Low:75.44
Close:81.90
52wk High:122.20
52wk Low:45.91
Shares:68.29M
Float Shares:55.48M
Volume Ratio:0.99
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1057
EPS(LYR):-3.1100
ROE:-90.45%
ROA:-27.51%
PB:37.23
PE(LYR):-24.38

Loading ...

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating

MT Newswires Live
·
Dec 12, 2025

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Dec 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill

Reuters
·
Dec 11, 2025

Rhythm Pharmaceuticals Shares up 12% After Positive Mid-Stage Data for Rare Disease Therapy

THOMSON REUTERS
·
Dec 11, 2025

BUZZ-Rhythm Pharma rises on positive mid-stage data for rare disease therapy

Reuters
·
Dec 11, 2025

BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome

Reuters
·
Dec 11, 2025

Rhythm Pharmaceuticals Inc - Plans Phase 3 Trial for Setmelanotide in Pws

THOMSON REUTERS
·
Dec 11, 2025

Rhythm Pharmaceuticals Inc: Safety and Tolerability Results Have Been Consistent With Setmelanotide's Well-Established Clinical Profile

THOMSON REUTERS
·
Dec 11, 2025

Rhythm Pharmaceuticals Announces Preliminary Phase 2 Data for Setmelanotide in Prader-Willi Syndrome

Reuters
·
Dec 11, 2025

Rhythm Pharmaceuticals to Announce Preliminary Data From Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

THOMSON REUTERS
·
Dec 11, 2025

The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com

Dow Jones
·
Dec 05, 2025

Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating

Simply Wall St.
·
Nov 29, 2025

How Positive Analyst Coverage at Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story

Simply Wall St.
·
Nov 27, 2025

Rhythm Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Nov 25, 2025

Citigroup Initiates Rhythm Pharmaceuticals at Buy With $136 Price Target

MT Newswires Live
·
Nov 25, 2025

Rhythm Pharmaceuticals initiated with a Buy at Citi

TIPRANKS
·
Nov 25, 2025

Rhythm Pharmaceuticals Chief Human Resources Officer Pamela J. Cramer Reports Disposal of Common Shares

Reuters
·
Nov 25, 2025

S&P 500 Futures Climb In Premarket Trading; Centene, Millicom Intl Cellular Lead

Dow Jones
·
Nov 24, 2025

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Reuters
·
Nov 20, 2025

FDA Review Extension for IMCIVREE Might Change the Case for Investing in Rhythm Pharmaceuticals (RYTM)

Simply Wall St.
·
Nov 17, 2025